Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 27, 2005 Stephen D. Simpson	AstraZeneca Shines, for Now The British-Swedish drug company has a great quarter, but the future looks dimmer.
The Motley Fool July 30, 2010 Cliff D'Arcy	Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline.
BusinessWeek June 28, 2004 Kerry Capell	Will This Superdrug Catch A Chill? Negative publicity could jeopardize Crestor, AstraZeneca's cholesterol-buster.
BusinessWeek June 2, 2011 Kresge & Connolly	A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies.
The Motley Fool October 26, 2006 Brian Lawler	Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results.
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
BusinessWeek October 4, 2004 Kerry Capell	Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving.
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
The Motley Fool July 27, 2006 Stephen D. Simpson	AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain.
The Motley Fool October 27, 2005 Stephen D. Simpson	AstraZeneca Prepares for a Dry Spell A weak late-stage pipeline will make for challenging earnings growth in the coming years. Investors may want to hold out for a better price here.
The Motley Fool October 14, 2010 Sean Williams	Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away.
The Motley Fool January 8, 2010 Brian Orelli	Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva.
The Motley Fool November 2, 2011 Prabhat Sakya	AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be?
The Motley Fool December 27, 2004 W.D. Crotty	Drug Safety: Investors Beware Will AstraZeneca become the latest casualty in the drug safety debate?
The Motley Fool April 28, 2005 Stephen D. Simpson	Standby Drugs Sustain AstraZeneca Sales are good now, but what will a weak pipeline mean to investors in a few years?
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool May 21, 2009 Robert Steyer	The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations?
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool October 30, 2008 Brian Orelli	What's on Deck for AstraZeneca? The drugmaker increases EPS by cutting costs, but it's the next move that will count the most.
The Motley Fool October 30, 2009 Brian Orelli	Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future.
The Motley Fool February 5, 2007 Billy Fisher	A Fresh Outlook at AstraZeneca Strong performance makes management happy at the European drug giant. As long as the company is able to continue the strong revenue growth from its major contributors, shareholders will be able to enjoy a prosperous 2007.
The Motley Fool November 10, 2008 Brian Orelli	Drug Fuels an Idling Rocket Ship AstraZeneca needs another FDA approval to really take advantage of its cholesterol drug's success.
The Motley Fool January 28, 2011 Alan Oscroft	AstraZeneca to Double Buybacks Regulatory setbacks have hit the drug firm's profits, but things look pretty resilient overall.
The Motley Fool August 31, 2010 Brian Orelli	A Mostly Meaningless FDA Rejection The Food and Drug Administration sends AstraZeneca back to the drawing board for the second time when it rejected motavizumab, the drugmaker's newest treatment for respiratory syncytial virus.
The Motley Fool July 27, 2010 Brian Orelli	Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant.
The Motley Fool May 22, 2008 Brian Lawler	All Is Not Lost for AstraZeneca's Iressa AstraZeneca's Iressa gets a little pep back.
The Motley Fool February 2, 2006 Stephen D. Simpson	AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here.
IndustryWeek January 1, 2004 John S. McClenahen	Expanding The Discovery Channel Additional R&D labs at AstraZeneca in Waltham, Mass., promise to aid in development of cancer and infectious disease drugs.
The Motley Fool December 28, 2005 Stephen D. Simpson	AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool December 1, 2008 Brian Orelli	It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies.
BusinessWeek November 29, 2004 Carey & Barrett	Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do.
BusinessWeek April 25, 2005 Catherine Arnst	When Patients Say: Don't Ban My Drug Emotional lobbying can keep a treatment on the market despite serious side effects.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool April 21, 2011 Brian Orelli	Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested.
BusinessWeek July 21, 2003 Amy Barrett	A Bare-Knuckle Battle over Cholesterol Drugs If AstraZeneca's Crestor is approved, rivals' stepped-up pitches will focus on safety
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
The Motley Fool May 26, 2006 Brian Gorman	AstraZeneca's Essential Investment The drugmaker seems to be jumping on the China bandwagon, but its investment makes sense, given the potential return.
The Motley Fool November 23, 2004 W.D Crotty	5 Drugs to Worry About? The recall of Merck's Vioxx raises concern among investors that there may be other pharmaceutical companies with potential legal exposure.
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
The Motley Fool June 2, 2010 Brian Orelli	Take Your Low Margins and Shove 'Em In an effort to help lower its budget problems, Greece told drugmakers it was slashing prices of drugs, take it or leave it. Novo Nordisk chose "leave it."
The Motley Fool February 1, 2008 Brian Lawler	AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool July 30, 2007 Brian Lawler	AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy.
The Motley Fool June 30, 2010 Brian Orelli	When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions.
Bio-IT World October 10, 2003 Kevin Davies	Iressa's Trials and Tribulations The Iressa experience highlights the enormous stakes surrounding breakthrough therapies.
The Motley Fool April 26, 2007 Brian Lawler	AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note.
The Motley Fool May 3, 2010 Brian Orelli	While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind.
The Motley Fool July 29, 2010 Brian Orelli	This FDA Panel Isn't Brilliant Why does AstraZeneca's blood thinner Brilinta work better outside the U.S. than here at home? The Food and Drug Administration's advisory panel didn't seem to have a good explanation, but they didn't appear to care much, either.
Chemistry World December 24, 2015 Jennifer Newton	AstraZeneca to buy Acerta for blood cancer drug AstraZeneca has agreed to buy a majority stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US.